ClinicalTrials.gg

Program

glofitamab

Also written as “Glofitamab” and “IV Glofitamab”.

Its studies are mostly in Lymphoma · Lymphoma, Non-Hodgkin · Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-Cell, led by Hoffmann-La Roche.

Furthest: phase 3, since May 26, 202013 company-led studies, 9 open or runningNext primary completion: Mar 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche139 open or runningphase 3since May 26, 2020Mar 7, 2017Mar 22, 2027phase 1 · NCT06624085

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 7, 2017First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT03075696 · 940 enrolled · United States, Australia, Belgium and more
  2. Mar 17, 2020Phase 1 study in Lymphoma, B-CellNCT04313608 · 23 enrolled · Australia
  3. May 26, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04408638 · 270 enrolled · United States, Australia, Belgium and more
  4. Dec 1, 2020Phase 1 study in LymphomaNCT04657302 · 30 enrolled · China
  5. Jul 19, 2021Phase 2 study in LymphomaNCT04980222 · 46 enrolled · United States, Denmark, France and more
  6. Nov 23, 2021Phase 1 study in Lymphoma, Non-HodgkinNCT05219513 · 53 enrolled · United States, Australia, Denmark and more
  7. Dec 13, 2021Phase 1 study in Lymphoma, Non-HodgkinNCT05169515 · 121 enrolled · United States, Israel, Italy and more
  8. May 3, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT05364424 · 43 enrolled · United States
  9. Sep 6, 2022Phase 2 study in RecurrenceNCT05533775 · 65 planned · United States, Australia, Brazil and more
  10. Sep 14, 20232 phase 3 studiesNCT06084936, NCT06047080
  11. Oct 1, 2024Phase 1 study in LymphomaNCT06624085 · 50 enrolled · United States, Puerto Rico
  12. Jan 21, 2025Phase 2 study in RecurrenceNCT06806033 · 130 planned · United States, Australia, Canada and more
  13. Nov 10, 2026Primary completion moved from 2027-01-31 to 2029-07-31Date moved laterphase 2 · +30 months · NCT06806033

Ahead

  1. Mar 22, 2027Primary completion: phase 1 study in LymphomaNCT06624085
  2. Aug 31, 2027Primary completion: phase 3 study in LymphomaNCT06084936
  3. Oct 1, 2027Primary completion: phase 3 study in Large B-Cell LymphomaNCT06047080
  4. Mar 31, 2028Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04408638

TargetBeta

CD3E →MS4A1 →read by rule
“B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mosunetuzumabruleHoffmann-La Rochephase 314
epcoritamabruleGenmabphase 313
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 13

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06806033Recurrence · United States, Australia, Canada and more2RecruitingJul 31, 2029130
NCT06624085Lymphoma · United States, Puerto Rico1Active, not recruitingMar 22, 202750
NCT06084936Lymphoma · United States, Australia, Brazil and more3RecruitingAug 31, 2027182
NCT06047080Large B-Cell Lymphoma · United States, Argentina, Australia and more3Active, not recruitingOct 1, 20271,130
NCT05533775Recurrence · United States, Australia, Brazil and more2RecruitingNov 30, 202965
NCT05364424Lymphoma, Large B-Cell, Diffuse · United States1CompletedOct 15, 202543
NCT05169515Lymphoma, Non-Hodgkin · United States, Israel, Italy and more1Active, not recruitingApr 30, 2029121
NCT05219513Lymphoma, Non-Hodgkin · United States, Australia, Denmark and more1TerminatedJul 17, 202453
NCT04980222Lymphoma · United States, Denmark, France and more2Active, not recruitingOct 24, 202446
NCT04657302Lymphoma · China1CompletedOct 25, 202230
NCT04408638Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more3Active, not recruitingMar 31, 2028270
NCT04313608Lymphoma, B-Cell · Australia1CompletedOct 26, 202123
NCT03075696Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more2Active, not recruitingMar 30, 2029940

How it is read

Names in the registry

  • “Glofitamab”, 12 entries
  • “IV Glofitamab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.